Lilly Q3 Results - Q3 Top Pharma Company Earnings Reports

View Lilly's Q3 Earnings Report

FiercePharma says: Lilly posted $941.8 million in third-quarter net income, way up from last year's $465.6 million loss on charges. More impressively, however, the company managed to boost sales by 6.8 percent during a quarter when its rivals had a tough time on the revenue side.. Read more of our coverage here...

Highlights:

  • Higher volume drives revenue growth
  • Stronger dollar results in improved gross margin
  • Earnings per share increase to $.86 (reported) or $1.20 (pro forma non-GAAP)
  • Full-year 2009 EPS guidance range revised to $3.90 - $4.00 (reported) or $4.30 - $4.40 (pro forma non-GAAP)

Check out Lilly's current earnings estimates from CNN Money

Lilly's Website: http://www.lilly.com/

Lilly Q3 Results - Q3 Top Pharma Company Earnings Reports
Read more on

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.